Colon Cancer Adjuvant Therapies Should Show 3-Year Disease-Free Survival, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee members voted unanimously that disease-free survival should be used as a primary endpoint for colon cancer treatment in the adjuvant setting. The committee also voted 8-5 that progression-free survival could be used for first-line therapies.